News AGN.c AGNPF progressing their Phase 1 DMT Clinical Stroke Study with the news that they dosed their first subject.
The resulting data generated will help AGN to plan both a Phase 2 acute stroke and rehabilitation study more effectively.
For more on DMT as a treatment for strokes here’s a video with the CEO.
Key points
- Currently only around 15% of people who suffered ischemic strokes have treatment options
- Ischemic stroke treatment is estimated to be a $15B market by 2029
- CEO explains how DMT can become a treatment for strokes
- Also touches on their Phase-1 clinical trial
- + more
https://www.youtube.com/watch?v=gMgSYNyMo34